No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Align Technology, Inc., a prominent medical device company, is dedicated to developing, producing, and commercializing innovative solutions for dental professionals. Its core offerings include the well-known Invisalign clear aligner system and the iTero line of intraoral scanners, complemented by associated services. The company caters to orthodontists, general dentists, and practitioners specializing in restorative and aesthetic dentistry. Its operations are primarily organized into two divisions: The Clear Aligner segment encompasses a comprehensive range of Invisalign products. This includes full treatment solutions like Invisalign comprehensive, tailored for adolescent patients and incorporating advanced features such as mandibular advancement, compliance indicators, and compensation for tooth eruption. It also offers specialized packages for younger children (typically ages seven to ten) with mixed dentition, known as Invisalign First Phase I and Invisalign First Comprehensive Phase 2. Beyond these extensive treatments, the segment provides less comprehensive options, including Invisalign moderate, lite, express packages, and Invisalign Go. Additionally, it supplies non-case related items such as retention devices, charges for Invisalign training, and sells supplementary products like cleaning materials and adjusting instruments utilized by dental professionals during treatment. The Scanners and Services segment focuses on the iTero scanner, a unified hardware platform equipped with various software functionalities for both restorative and orthodontic procedures. Its software for restorative dentistry serves general practitioners, prosthodontists, periodontists, and oral surgeons, while the orthodontic software aids practitioners in digital record keeping, diagnosis, and the creation of printed models and retainers. This segment further extends its offerings with computer-aided design and manufacturing (CAD/CAM) services, essential accessories like disposable wand sleeves, iTero models and dies, and supports third-party scanners and digital scans. Noteworthy innovations include the Invisalign Outcome Simulator, a chairside and cloud-based application for the iTero scanner, the Invisalign Progress Assessment Tool, and TimeLapse technology, which enables clinicians to compare a patient's historical 3D scans with current data. Align Technology distributes its products across global markets, including significant presence in the United States, Switzerland, and China. Established in 1997, the company maintains its corporate headquarters in Tempe, Arizona.
www.aligntech.comNo one on the platform currently holds 0HCK.L.
No tracked institution reports a position in 0HCK.L as of their last filing.
No one on the platform has traded 0HCK.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 15.7% | 17.9% | 34.5% | — | — | — |
| Rev. Growth % | 0.9% | 10.3% | ||||
| Profit Margin % | 10.2% | 12.3% | 20.5% | |||
| Free Cash Flow Margin % | 12.2% | 14.1% | 16.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.2B | +3.6% | $11.29 | $11.12–$11.46 | — | 1 |
| 2027 | $4.3B | +4.0% | $12.54 | $12.35–$12.73 | — | 1 |
| 2028 | $4.6B | +5.2% | $13.78 | $13.57–$13.99 | — | 1 |
| 2029 | $4.9B | +6.4% | $15.35 | $15.11–$15.58 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $2.62 | $2.64 | +0.8% |
| 2026-04-29 | $2.30 | $2.58 | +12.2% |
| 2026-02-04 | $2.97 | $3.29 | +10.8% |
| 2025-10-29 | $2.40 | $2.61 | +8.8% |
| 2025-07-30 | $2.57 | $2.49 | -3.1% |
| 2025-04-30 | $1.99 | $2.13 | +7.0% |
| 2025-02-05 | $2.45 | $2.44 | -0.4% |
| 2024-10-23 | $2.31 |
| $2.35 |
| +1.7% |
| +0.62% |
| $15.1B |
| — |
| 0J2O.LHalozyme Therapeutics, Inc. | $106.52 | -1.73% | $12.6B | — |
| 0JZ2.LMasimo Corporation | $179.96 | +0.01% | $9.5B | — |
Source: Financial Modeling Prep · peers by sector/industry